TY - JOUR
T1 - Natural history of undifferentiated pleomorphic sarcoma
T2 - Experience from the US Sarcoma Collaborative
AU - Makris, Eleftherios A.
AU - Tran, Thuy B.
AU - Delitto, Daniel J.
AU - Lee, Byrne
AU - Ethun, Cecilia G.
AU - Grignol, Valerie
AU - Harrison Howard, J.
AU - Bedi, Meena
AU - Clark Gamblin, T.
AU - Tseng, Jennifer
AU - Roggin, Kevin K.
AU - Chouliaras, Konstantinos
AU - Votanopoulos, Konstantinos
AU - Cullinan, Darren
AU - Fields, Ryan C.
AU - Cardona, Kenneth
AU - Poultsides, George
AU - Kirane, Amanda
N1 - Publisher Copyright:
© 2024 Wiley Periodicals LLC.
PY - 2024/6
Y1 - 2024/6
N2 - Background: Undifferentiated pleomorphic sarcoma (UPS) is a relatively rare but aggressive neoplasm. We sought to utilize a multi-institutional US cohort of sarcoma patients to examine predictors of survival and recurrence patterns after resection of UPS. Methods: From 2000 to 2016, patients with primary UPS undergoing curative-intent surgical resection at seven academic institutions were retrospectively reviewed. Epidemiologic and clinicopathologic factors were reviewed by site of origin. Overall survival (OS), recurrence-free survival (RFS), time-to-locoregional (TTLR), time-to-distant recurrence (TTDR), and patterns of recurrence were analyzed. Results: Of the 534 UPS patients identified, 53% were female, with a median age of 60 and median tumor size of 8.5 cm. The median OS, RFS, TTLR, and TTDR for the entire cohort were 109, 49, 86, and 46 months, respectively. There were no differences in these survival outcomes between extremity and truncal UPS. Compared with truncal, extremity UPS were more commonly amenable to R0 resection (87% vs. 75%, p = 0.017) and less commonly associated with lymph node metastasis (1% vs. 6%, p = 0.031). R0 resection and radiation treatment, but not site of origin (extremity vs. trunk) were independent predictors of OS and RFS. TTLR recurrence was shorter for UPS resected with a positive margin and for tumors not treated with radiation. Conclusion: For patients with resected extremity and truncal UPS, tumor size >5 cm and positive resection margin are associated with worse survival OS and RFS, irrespectively the site of origin. R0 surgical resection and radiation treatment may help improve these survival outcomes.
AB - Background: Undifferentiated pleomorphic sarcoma (UPS) is a relatively rare but aggressive neoplasm. We sought to utilize a multi-institutional US cohort of sarcoma patients to examine predictors of survival and recurrence patterns after resection of UPS. Methods: From 2000 to 2016, patients with primary UPS undergoing curative-intent surgical resection at seven academic institutions were retrospectively reviewed. Epidemiologic and clinicopathologic factors were reviewed by site of origin. Overall survival (OS), recurrence-free survival (RFS), time-to-locoregional (TTLR), time-to-distant recurrence (TTDR), and patterns of recurrence were analyzed. Results: Of the 534 UPS patients identified, 53% were female, with a median age of 60 and median tumor size of 8.5 cm. The median OS, RFS, TTLR, and TTDR for the entire cohort were 109, 49, 86, and 46 months, respectively. There were no differences in these survival outcomes between extremity and truncal UPS. Compared with truncal, extremity UPS were more commonly amenable to R0 resection (87% vs. 75%, p = 0.017) and less commonly associated with lymph node metastasis (1% vs. 6%, p = 0.031). R0 resection and radiation treatment, but not site of origin (extremity vs. trunk) were independent predictors of OS and RFS. TTLR recurrence was shorter for UPS resected with a positive margin and for tumors not treated with radiation. Conclusion: For patients with resected extremity and truncal UPS, tumor size >5 cm and positive resection margin are associated with worse survival OS and RFS, irrespectively the site of origin. R0 surgical resection and radiation treatment may help improve these survival outcomes.
KW - sarcoma
KW - soft tissue sarcoma
KW - undifferentiated pleomorphic sarcoma
UR - http://www.scopus.com/inward/record.url?scp=85189818804&partnerID=8YFLogxK
U2 - 10.1002/jso.27620
DO - 10.1002/jso.27620
M3 - Article
C2 - 38562002
AN - SCOPUS:85189818804
SN - 0022-4790
VL - 129
SP - 1354
EP - 1363
JO - Journal of surgical oncology
JF - Journal of surgical oncology
IS - 7
ER -